Conditions: Adult Attention Deficit Hyperactivity Disorder
Keywords: ADHD Attention deficit hyperactivity disorder
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 341
Healthy volunteers: no

Brief summary:
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).

Detailed description:
This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4 or 8 mg SEP 225289 once daily \[QD\]) versus placebo over a 4 week treatment period.

Arms:
arm 1: SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses arm 2: SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses arm 3: 4 capsules of placebo

Interventions: intervention 1: SEP-225289 intervention 2: SEP-225289 intervention 3: Placebo
Intervention descriptions: intervention 1: SEP-225289 4mg once daily intervention 2: SEP-225289 8mg once daily intervention 3: Placebo once daily

Protocol document: